Novartis' Cosentyx wins FDA nod as first anti-IL-17 biologic for PMR
Novartis just scored FDA approval for Cosentyx (secukinumab) 150 mg in polymyalgia rheumatica, making it the first and only anti-IL-17 biologic cleared for the disease. It's the 11th US indication for the drug, and it hands patients an alternative to the long steroid courses that dominate PMR care.
- Original source: finance.yahoo.com.
- The source published it on Nov 16, 2026 at 4:00 PM.
- No second outlet has reported it yet. Treat it as a single-source claim.
The FDA approved Cosentyx at 150 mg for adults with polymyalgia rheumatica who have responded poorly to corticosteroids or can't handle tapering off them. Novartis announced the green light on November 17, 2026, from Basel. It's the first and only anti-IL-17 biologic approved for PMR, a condition that mostly hits adults over 50.
The Phase III REPLENISH trial backed the filing: secukinumab doubled sustained remission rates and showed steroid-sparing effects compared with placebo. "In the Phase III REPLENISH trial, secukinumab doubled the likelihood of sustained remission while helping patients taper off steroids, which should be the goal of PMR treatment," said Prof. John Stone, professor of medicine at Harvard Medical School and Massachusetts General Hospital, and global principal investigator for the trial.
Roughly 966,000 people in the US live with PMR, which brings acute pain and stiffness in the shoulders, neck and hips. Steroids are the standard treatment, but up to 40% of patients relapse within the first year, and long-term use raises the risk of osteoporosis, cardiovascular disease and diabetes. "For years, patients have had too few treatment options," said Seth Ginsberg, co-founder and president of the Global Healthy Living Foundation and CreakyJoints.
This is the 11th US indication for Cosentyx, which Novartis says rests on more than a decade of clinical experience across immune-mediated diseases. The PMR indication is already approved in the EU, with further regulatory reviews still in play, including in Japan.
TopicsNovartis · Cosentyx · secukinumab · FDA · REPLENISH trial · John Stone · Global Healthy Living Foundation · Seth Ginsberg
Source: finance.yahoo.com
Written by AI from verified reporting.
More stories
- Health & science casrai.org 0 viewsFDA greenlights giredestrant-everolimus duo for ESR1-mutated breast cancer
- Health & science nbcnews.com Caught by @nina.anggraini29 0 viewsMeasles Is Endemic Again as the U.S. Loses Its Elimination Status
- Health & science aol.com 1 viewFDA Clears FoundationOne Liquid CDx as First Companion Test for WILSERDLY Combo
- Health & science statnews.com 1 viewFDA approves Roche's Wilserdly for resistant breast cancer

